文献速递角膜与眼表疾病

NOV03治疗与睑板腺功能障碍相关的干眼症体征和症状:随机3期MOJAVE研究

NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study.
PubMed 文献 · Am J Ophthalmol · 2023-03-21

这项随机、双盲、对照3期试验将620例有干眼症病史且伴睑板腺功能障碍体征的成人患者按1:1随机分配至NOV03(全氟己基辛烷)滴眼液或低渗盐水(0.6%)每日4次治疗8周。第8周时,NOV03在总角膜荧光素染色和眼干燥评分两项主要终点上均显著优于盐水,眼部不良事件发生率两组相似(12.9% vs 12.3%),无严重不良事件。

要点

  • NOV03在第8周总角膜荧光素染色较基线变化为-2.3,盐水为-1.1,组间差异有统计学意义(P < .001)。
  • NOV03在第8周眼干燥视觉模拟评分较基线变化为-29.4,盐水为-19.2,组间差异有统计学意义(P < .001)。
  • NOV03眼部不良事件发生率为12.9%,盐水为12.3%,无严重不良事件及导致停药的不良事件。

核心结论

  • 在伴睑板腺功能障碍的干眼症患者中,NOV03与低渗盐水对照相比显著改善了干眼症的体征和症状。
  • NOV03耐受性良好,不良事件特征与盐水相似。

研究设计与样本

  • 随机、双盲、对照3期试验(MOJAVE研究)。
  • 纳入≥18岁、有干眼症病史且伴睑板腺功能障碍体征的患者,按1:1随机分配至NOV03或低渗盐水(0.6%)每日4次治疗8周。
  • 共620例患者被随机并接受治疗(NOV03组n=311,盐水组n=309)。

主要发现

  • 第8周总角膜荧光素染色(国家眼科研究所量表)较基线最小二乘均值变化:NOV03组-2.3 vs 盐水组-1.1,最小二乘均值治疗差异-1.2(95%CI -1.7至-0.8),P < .001。
  • 第8周眼干燥视觉模拟评分(0-100)较基线最小二乘均值变化:NOV03组-29.4 vs 盐水组-19.2,最小二乘均值治疗差异-10.2(95%CI -14.4至-6.1),P < .001。
  • 组间差异早在第2周即观察到有统计学意义。
  • 眼部不良事件发生率:NOV03组12.9% vs 盐水组12.3%。
  • 无严重不良事件,无导致治疗中断的不良事件。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy and safety of NOV03 (perfluorohexyloctane) ophthalmic drop for the treatment of signs and symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD). DESIGN: Randomized, double-masked, controlled trial. METHODS: Patients ≥18 years of age with a history of DED and signs of MGD were randomly assigned 1:1 to treatment with NOV03 or hypotonic saline (0.6%) 4 times daily for 8 weeks. The primary sign and symptom endpoints were change from baseline to week 8 in total corneal fluorescein staining (tCFS; National Eye Institute scale) and eye dryness score (0-100 visual analog scale), respectively. RESULTS: A total of 620 patients (NOV03, n = 311; saline, n = 309) were randomized and treated. Least-squares (LS) mean change from baseline to week 8 was statistically significantly greater for NOV03 compared with saline for both tCFS (-2.3 vs -1.1; LS mean treatment difference, -1.2 [95% confidence interval -1.7 to -0.8]; P < .001) and visual analog scale dryness score (-29.4 vs -19.2; LS mean treatment difference, -10.2 [95% CI -14.4 to -6.1]; P < .001), with statistically significant between-group differences observed as early as week 2. The incidence of ocular adverse events was similar for NOV03 (12.9%) and saline (12.3%). There were no serious adverse events and no adverse events leading to treatment discontinuation. CONCLUSIONS: In this randomized controlled trial of patients with DED associated with MGD, NOV03 significantly reduced both signs and symptoms of DED compared with hypotonic saline control. NOV03 was well tolerated, with an adverse event profile similar to that of saline.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sheppard JD, Kurata F, Epitropoulos AT, et al. NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study. Am J Ophthalmol. 2023. PMID: 36948372. doi:10.1016/j.ajo.2023.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。